D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with NSCLC: Phase 1 Study Results.
Ziming Li,Zhengbo Song,Yanqiu Zhao,Pingli Wang,Liyan Jiang,Yi Gong,Jianying Zhou,Hong Jian,Xiaorong Dong,Wu Zhuang,Shundong Cang,Nong Yang,Jian Fang,Jianhua Shi,Junguo Lu,Rui Ma,Ping Wu,Yingqian Zhang,Mengmeng Song,Chun-Wei Xu,Zhe Shi,Ling Zhang,Yaolin Wang,Xicheng Wang,Yiping Zhang,Shun Lu
DOI: https://doi.org/10.1016/j.jtho.2023.03.015
IF: 20.121
2023-01-01
Journal of Thoracic Oncology
Abstract:Introduction: D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D-1553 in patients with KRAS G12C-mutated NSCLC in multiple sites in the People's Republic of China. Methods: Patients with KRAS G12C-mutated NSCLC have administrated D-1553 600 mg orally once daily, 800 mg once daily, 1200 mg once daily, 400 mg twice a day, or 600 mg twice a day in dose escalation. In dose-expansion, all patients received 600 mg twice a day. The safety, pharma-cokinetics, and efficacy of D-1553 were evaluated.Results: Among a total of 79 treated patients, 75 patients (94.9%) reported treatment-related adverse events with 30 patients experiencing grade 3 or 4 events (38.0%). Most of the adverse events were manageable and the patients tolerated the study treatment well. Among 74 patients assessable for efficacy analysis, 30 patients had a partial response and 38 had stable disease with a confirmed objective response rate (ORR) and disease control rate (DCR) of 40.5% and 91.9%, respectively. The median progression -free survival was 8.2 months, and the median duration of response was 7.1 months. Among 62 patients assessable for response at the recommended phase 2 dose, partial response occurred in 24 patients (ORR, 38.7%) and stable disease in 32 patients (DCR, 90.3%). The median progression-free survival and duration of response were 7.6 months and 6.9 months, respectively. In patients with brain metastasis, ORR and DCR were 17% and 100%, respectively. Conclusions: D-1553 represents a promising therapeutic option for patients with KRAS G12C-mutated NSCLC with a well-tolerated safety profile and encouraging antitumor activity.& COPY; 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.